Results
A total of 41 studies were included in this scoping review. The study selection process is presented in a PRISMA flow diagram ( Fig. 1 ). Each included study is assigned an identification number (study ID) in Table 1 . The studies were conducted in eight different Western and developed countries: The United States of America (26/41), Canada (5/41), Colombia (3/41), Denmark (2/41), France (2/41), the United Kingdom (1/41), Italy (1/41) and Spain (1/41). A total of 34,269 participants were included in the studies, with sample sizes ranging from 10 to 11,334. All the studies were quantitative, of which 11 had prospective designs (study IDs 5, 6, 11, 13–15, 25, 26, 31, 37, 38). The analysed data had been retrieved between January of 1991 to October of 2022, mostly from medical records and registries. The data was collected from the patients between 2 weeks to 12 months postoperatively, most commonly for approximately 30 days (19/41) ( Table 1 ). Five studies did not report the follow-up time for data collection (study IDs 9, 12, 21, 25, 32). More details on study characteristics are provided in Table 1 . The samples in two of the studies are likely to overlap (study IDs 27 and 30). Therefore, only the number of incidents extracted from Philp et al. (study ID 30) are included in counts of the harmful incidents that were reported in both studies, as these data were collected more recently and over a longer period. Table 1 Study identification numbers (study ID), study characteristics and outcomes relevant to the scoping review. Table 1 dummy alt text STUDY ID FIRST AUTHOR (YEAR), COUNTRY STUDY SETTING, SAMPLE SIZE AND DATA COLLECTION FOLLOW-UP TIME STUDY OBJECTIVES OUTCOMES 1 Bazzurini et al. (2022) , Italy Setting: One national referral cancer centre. Sample size: 138. Data collection follow-up time: Up to 60 days. To develop a same-day discharge setting for laparoscopic treatment of adnexal disease. Adverse events. 2 Behbehani et al. (2020) , USA Setting: One tertiary academic care centre. Sample size: 441. Data collection follow-up time: 2 weeks. To determine factors that predict urinary retention after same-day discharge minimally invasive hysterectomy. Patient reported symptoms of urinary tract infection. 3 Benoit et al. (2022) , France Setting: Three hospitals. Sample size: 153. Data collection follow-up time: 1 month. To assess the feasibility and safety of total hysterectomy by laparoscopic approach in outpatient surgery. Factors associated with readmission and reoperation. 4 Delgado et al. (2021) , USA Setting: One academic-affiliated community hospital. Sample size: 176. Data collection follow-up time: 6 weeks. To identify incidents of and risk factors for urinary retention after outpatient hysterectomy. Data on urinary retention, pain and other symptoms. 5 Duffy et al. (2005) , United Kingdom Setting: Day surgery and outpatient units in three hospitals. Sample size: 22. Data collection follow-up time: 3 months. To compare patient satisfaction, discomfort, procedure time, success rate and adverse events of hysteroscopic versus laparoscopic sterilisation. Patient discomfort and postoperative adverse events. 6 Gale et al. (2018) , Canada Setting: One tertiary academic referral centre. Sample size: 44. Data collection follow-up time: 6 months. To evaluate the feasibility of same-day discharge after laparoscopic hysterectomy, not excluding patients with complex surgical pathology and medical comorbidities. Pain level, nausea and constipation. 7 Groth et al. (2022) , Denmark Setting: One department of gynaecology and obstetrics. Sample size: 728. Data collection follow-up time: 30 days. To examine the feasibility of same-day discharge after pelvic organ prolapse surgery and investigate the cause of hospital contact after discharge. Reasons for patient initiated contact and complications confirmed by gynaecologist. 8 Guerrero-Machado et al. (2021) , Colombia Setting: One hospital. Sample size: 67. Data collection follow-up time: Up to 22 days. To describe the safety of discharge within 12 h after laparoscopic hysterectomy for benign uterine disease. Safety variables such as complications. 9 Gunnala et al. (2016) , USA Setting: One study centre. Sample size: 207. Data collection follow-up time: Not reported. To assess surgical outcomes and evaluate feasibility of same-day discharge after robot assisted myomectomy for myomas ≥9 cm. Major adverse outcomes such as postoperative infection or abscess formation. 10 Lee et al. (2014) , USA Setting: One institution. Sample size: 157. Data collection follow-up time: 30 days. To evaluate the feasibility and safety of same-day discharge after robot assisted hysterectomy with or without other procedures for benign and malignant conditions. Reasons for postoperative health care visits/evaluations and readmissions. 11 Liu et al. (2019) , USA Setting: One ambulatory clinic at a tertiary institution. Sample size: 23. Data collection follow-up time: 6 weeks. To determine safety and feasibility of same-day discharge in patients undergoing vaginal hysterectomy with pelvic floor reconstruction. Postoperative complications. 12 Lloyd et al. (2018) , USA Setting: One tertiary care referral centre. Sample size: 10. Data collection follow-up time: Not reported. To assess short term safety and patient satisfaction with same-day discharge after robotic assisted pelvic floor reconstructive procedures. Postoperative outcomes. 13 Maheux-Lacroix et al. (2015) , Canada Setting: One tertiary hospital centre. Sample size: 128. Data collection follow-up time: 3 months. To estimate feasibility and safety of total laparoscopic hysterectomy as an outpatient procedure for benign conditions. Complications. 14 Mathew et al. (2022) , USA Setting: One tertiary referral centre. Sample size: 29. Data collection follow-up time: 4 weeks. To asses patient preference and satisfaction with same-day discharge following transvaginal and minimally invasive apical pelvic organ prolapse repair surgery during the COVID-19 pandemic. Patients' postoperative perspectives and complications. 15 Minig et al. (2015) , Spain Setting: One comprehensive cancer centre. Sample size: 24. Data collection follow-up time: 30 days. To evaluate the feasibility and safety of multimodal perioperative care after laparoscopic hysterectomy. Postoperative complications. 16 Moss et al. (2022) , USA Setting: One tertiary university-affiliated institution. Sample size: 142. Data collection follow-up time: 30 days. To compare short term outcomes of same-day discharge with planned admission in patients undergoing apical pelvic organ prolapse repair. Complications after surgery. 17 Penner et al. (2015) , USA Setting: Two study centres. Sample size: 118. Data collection follow-up time: 6 weeks. To evaluate feasibility and safety of same-day discharge minimally invasive comprehensive surgical staging for endometrial and cervical cancer. (Main surgical treatment: Hysterectomy.) Postoperative complications. 18 Raju et al. (2022) , USA Setting: A multicentre nationwide cohort. Sample size: 362. Data collection follow-up time: 30 days. To investigate trends and outcomes of ambulatory minimally invasive sacrocolpopexy (pelvic organ prolapse surgery). Postoperative outcomes. 19 Ross et al. (2022) , USA Setting: One tertiary referral centre. Sample size: 59. Data collection follow-up time: 30 days. To compare the rates of urinary tract infection after apical pelvic organ prolapse surgery between patients undergoing same-day discharge and overnight recovery. Postoperative variables such as postoperative urinary tract infections. 20 Tannus et al. (2022) , USA Setting: One centre at a tertiary academic hospital. Sample size: 618. Data collection follow-up time: 6 weeks. To investigate the feasibility and predictive factors for same-day discharge after robot assisted hysterectomy for benign indications. Postoperative variables. 21 Thomas et al. (2010) , USA Setting: One centre for assisted reproduction. Sample size: 189. Data collection follow-up time: Not reported. To evaluate the efficacy and safety of mini laparotomy myomectomy in an ambulatory setting. Postoperative complications. 22 Wield et al. (2022) , USA Setting: One centre at a women’s hospital. Sample size: 775. Data collection follow-up time: 30 days. To determine feasibility and safety of same-day discharge after minimally invasive hysterectomy in gynaecologic oncology. Postoperative complications. 23 Zhang et al. (2022) , USA Setting: Two university-affiliated hospitals. Sample size: 132. Data collection follow-up time: 30 days. To assess the safety of same-day discharge following robot assisted endometrial cancer staging and identify risk factors for postoperative admission. (Main surgical treatment: Hysterectomy.) Reasons for emergency department visits or admissions after discharge. 24 Berger et al. (2020) , USA Setting: A care organisation of 4.5 million members. Sample size: 5506. Data collection follow-up time: 30 days. To compare the effect of same-day discharge on readmission risk after minimally invasive pelvic reconstructive surgery. Reasons for hospital readmission and emergency department visits. 25 Calle et al. (2011) , Colombia Setting: Gynaecological endoscopy unit of one clinic. Sample size: 297. Data collection follow-up time: Not reported for all data. Pain assessment: 12 days. To present the experience observed in a cohort of patients undergoing ambulatory total laparoscopic hysterectomy. Postoperative outcomes, including complications, nausea and vomiting and pain. 26 Christiansen et al. (2019) , Denmark Setting: A regional teaching hospital. Sample size: 76. Data collection follow-up time: 28 days. To investigate whether outpatient total laparoscopic hysterectomy could be performed as a routine without compromising patient satisfaction. Complications. 27 Gien et al. (2011) , Canada Setting: One tertiary care academic teaching hospital. Sample size: 147. Data collection follow-up time: 3 weeks. To evaluate feasibility of same-day discharge after laparoscopic gynaecologic oncology surgery. (Main surgical treatment: Hysterectomy or trachelectomy.) Reasons for hospital admission. 28 Melamed et al. (2016) , USA Setting: Urban tertiary care centre at a teaching hospital. Sample size: 295. Data collection follow-up time: 30 days. To investigate complications after same-day discharge laparoscopic hysterectomy for endometrial cancer and intraepithelial neoplasia. Postoperative complications that occurred after surgery. 29 Perron-Burdick et al. (2011) , USA Setting: Data from care system register. Sample size: 527. Data collection follow-up time: 12 months. To estimate readmission rates and emergency care use by patients discharged home the same day after laparoscopic hysterectomy. Reasons for readmissions and urgent clinic or emergency department visits. 30 Philp et al. (2017) , Canada Setting: One institution. Sample size: 75. Data collection follow-up time: 30 days. To evaluate the safety and feasibility of same-day discharge after laparoscopic radical hysterectomy for cervix cancer. Reasons for unplanned health care encounters, readmissions and reoperations. 31 Rambeaud et al. (2017) , France Setting: One centre at a university hospital. Sample size: 13. Data collection follow-up time: 2 months. To evaluate the feasibility of outpatient laparoscopic sacrocolpopexy (pelvic organ prolapse surgery). Reasons for consultation with a doctor/ emergency department following surgery and postoperative pain. 32 Rendón et al. (2016) , Colombia Setting: One cancer institution. Sample size: 31. Data collection follow-up time: Not reported. To report the feasibility of outpatient laparoscopic radical hysterectomy in patients with early-stage cervical cancer. Postoperative complications and pain. 33 Rettenmaier et al. (2012) , USA Setting: A tertiary institution. Sample size: 21. Data collection follow-up time: 23 days. To evaluate same-day discharge in clinical stage I endometrial cancer patients treated with total laparoscopic hysterectomy, salpingo-oophorectomy and pelvic lymph node dissection. Postoperative complications. 34 Rivard et al. (2015) , USA Setting: A university hospital. Sample size: 90. Data collection follow-up time: 30 days. To determine factors for safe outpatient robot assisted minimally invasive gynaecologic oncology surgery. (Main surgical treatment: Hysterectomy, salpingo-oophorectomy or trachelectomy.) Postoperative complications. 35 Romanova et al. (2020) , USA Setting: One tertiary care institution at a women’s hospital. Sample size: 258. Data collection follow-up time: 30 days. To evaluate unanticipated healthcare encounters after same-day discharge major pelvic organ prolapse surgery and assess postoperative complications and severity. Reasons for unplanned healthcare encounters after surgery. 36 Schiff et al. (2019) , USA Setting: The American College of Surgeons National Surgical Quality Improvement Program database. Sample size: 6000. Data collection follow-up time: 30 days. To assess the effect of length of hospital stay on 30-day postoperative outcomes after minimally invasive hysterectomy. Surgical site infections (superficial, incisional, and/or organ space) and urinary tract infections. 37 Stovall et al. (1992) , USA Setting: A regional medical centre. Sample size: 35. Data collection follow-up time: 6 weeks. To determine the feasibility and safety of outpatient vaginal hysterectomy and patient acceptance of the procedure. Safety variables such as reasons for readmission. 38 Casas-Puig et al. (2024) , USA Setting: One tertiary care centre. Sample size: 76. Data collection follow-up time: 6 weeks. To describe the success of same-day discharge following vaginal hysterectomy and native-tissue colpopexy (pelvic organ prolapse surgery). Adverse events and pain. 39 Burdette et al. (2025) , USA Setting: One hospital. Sample size: 1029. Data collection follow-up time: 60 days. To evaluate safety of same-day discharge minimally invasive hysterectomy for endometrial cancer and intraepithelial neoplasia in patients with and without morbid obesity. Complications after surgery. 40 Dieter et al. (2022) , USA Setting: The American College of Surgeons National Surgical Quality Improvement Program database. Sample size: 3717. Data collection follow-up time: 30 days. To examine correlation between length of stay and postoperative complications following minimally invasive apical pelvic organ prolapse repair. Postoperative complications. 41 Milman et al. (2024) , Canada Setting: The American College of Surgeons National Surgical Quality Improvement Program database. Sample size: 11,334. Data collection follow-up time: 30 days. To assess same-day discharge and morbidity after minimally invasive hysterectomy for oncologic indication. Postoperative morbidity.
Study identification numbers (study ID), study characteristics and outcomes relevant to the scoping review.
An overview of the surgical approaches in the included studies and the treatments conducted with each approach is presented in Table 2 . Four studies included surgeries by vaginal approach only (study IDs 7, 11, 37, 38). Of the 37 studies that included laparoscopies, 20 specified that robot assisted surgeries were conducted (study IDs 2, 3, 9, 10, 12, 14, 17–20, 22–24, 28, 33–35, 39–41). While three studies reported to have included laparoscopic assisted vaginal hysterectomy (study IDs 24, 35, 41), two studies specified to have excluded this surgical approach (study IDs 13, 29). Furthermore, four of the studies that included hysterectomy by laparoscopic approach noted to have performed vaginal specimen retrieval (study IDs 15, 23, 32, 33). Mini laparotomies were usually conducted in combination with laparoscopy and for specimen retrieval in studies including hysterectomy (study IDs 6, 15, 22, 23, 26), salpingo-oophorectomy (study IDs 15, 22, 23, 26), lymphadenectomy (study IDs 22, 23) and myomectomy (study ID 21). Table 2 Surgical approaches and treatments in included studies. Table 2 dummy alt text SURGICAL APPROACH AND TREATMENT STUDY ID NUMBER OF STUDIES Laparoscopic Hysterectomy Salpingo-oophorectomy Pelvic organ prolapse surgery Lymphadenectomy Ovarian cyst removal Myomectomy Sterilisation Trachelectomy 1–6, 8–10, 12–36, 39–41 2–4, 6, 8, 10, 12, 13, 15–17, 19, 20, 22–30, 32–41 1, 3, 9, 10, 15, 17, 20, 22, 23, 26, 27, 33, 34, 37 2, 12, 14, 16, 18, 19, 24, 31, 35, 38, 40 10, 17, 22, 23, 27, 30, 33, 34, 41 1, 9 9, 21 5 34 37 32 14 11 9 2 2 1 1 Vaginal Pelvic organ prolapse surgery Hysterectomy Salpingo-oophorectomy Trachelectomy 2, 7, 11, 14, 16, 19, 24, 27, 35–38, 40 2, 7, 11, 14, 16, 19, 24, 27, 35, 40 2, 7, 16, 19, 24, 35–38, 40 37 27 13 10 10 1 1 Note: Information regarding surgical approaches are highlighted in bold text.
Surgical approaches and treatments in included studies.
Note: Information regarding surgical approaches are highlighted in bold text.
The main surgical treatments conducted were hysterectomy, pelvic organ prolapse surgery, salpingo-oophorectomy, lymphadenectomy, trachelectomy, myomectomy, ovarian cyst removal and sterilisation. These treatments were also conducted concurrently with one another, as shown in Fig. 2 . Other concurrent gynaecological and non-gynaecological treatments were procedures for urinary incontinence (study IDs 11, 12, 14, 16, 19, 38), hysteroscopy (study IDs 9, 21), cystoscopy (study ID 17), exploration of the abdominal cavity, salpingectomy (study IDs 9, 38), oophorectomy (study ID 38), adhesiolysis (study IDs 1, 22), ureterolysis (study ID 22), chromotubation, resection of endometriosis (study ID 9), appendectomy (study IDs 10, 23, 34), hernia repair (study ID 22), omentectomy (study IDs 10, 23, 27, 34), omental surgery (study ID 22), omental biopsy (study ID 23), peritoneal sampling (study IDs 1, 23), sentinel lymph node biopsy (study ID 30), staging of borderline ovarian tumour (study ID 1) and debulking (removal of metastases) (study ID 34). Surgical treatments for oncologic indications were included in 13 of the studies (study IDs 1, 10, 17, 22, 23, 27, 28, 30, 32–34, 39, 41). Fig. 2 The number of studies including the surgical treatments. Fig. 2 dummy alt text
The number of studies including the surgical treatments.
All of the identified harmful incidents are listed in Table 3 , mapped under the dimensions of harm based on WHO’s framework (2010) ; physiological harm and psychological harm. No social harmful incidents were identified from the studies included in this scoping review, and thus none are mapped. Table 4 provides an overview of the total number of incidents reported within the main categories of harmful incidents following each of the main surgical treatments. Table 3 Harmful incidents mapped under dimensions of harm, number of studies reporting the harmful incident, total number of harmful incidents reported and identification numbers (study ID) for studies reporting the harmful incident. Table 3 dummy alt text HARMFUL INCIDENTS NUMBER OF STUDIES REPORTING THE HARMFUL INCIDENT/ TOTAL NUMBER OF INCLUDED STUDIES TOTAL NUMBER OF INCIDENTS/ TOTAL NUMBER OF PARTICIPANTS IN STUDIES REPORTING THE NUMBER OF INCIDENTS STUDY ID FOR STUDIES REPORTING THE HARMFUL INCIDENT PHYSIOLOGICAL HARM Bleeding 23/41 139/11,339 (1.23 %) 1, 3, (5,) 6, 7, 8, 10, 13, 14, 17, 20, 21, 22, 23, 24, 25, 26, (27,) 28, 29, 30, 35, 39 Vaginal bleeding 13/41 39/7851 (0.50 %) 3, 6, 7, 8, 13, 17, 23, 24, 25, 26, (27,) 29, 30 Intraperitoneal bleeding 4/41 7/297 (2.36 %) 6, 8, 10, 14 Postoperative infections 32/41 1038/33,454 (3.10 %) 2, 3, 5, 6, 7, 8, 9, 10, 11, 12, 13, 16, 17, 18, 19, 20, 21, 22, 24, 25, 26, (27,) 28, 29, 30, 33, 35, 36, 38, 39, 40, 41 Urinary tract infection 19/41 549/29,899 (1.84 %) 2, 8, 11, 12, 13, 16, (18,) 19, 22, 24, 25, (27,) 28, (35,) 36, 38, 39, 40, 41 Surgical site infection 18/41 310/30,117 (1.03 %) 5, 6, 13, 17, (18,) 21, 22, 24, 25, 26, 29, 33, 35, 36, 38, 39, 40, 41 – vaginal cuff infection 7/41 28/1923 (1.46 %) 6, 13, 22, 25, 26, 29, 38 Pelvic infection 7/41 162/21,604 (0.75 %) 3, 9, 17, 30, 36, 40, 41 Other infections and inflammations 8/41 56/11,434 (0.49 %) 3, 5, 13, 22, 24, (35,) 40, 41 Sepsis 3/41 44/10,357 (0.42 %) 24, 40, 41 Pelviperitonitis 1/41 1/153 (0.65 %) 3 Reflux oesophagitis 1/41 1/22 (4.55 %) 5 Gastritis 1/41 2/128 (1.56 %) 13 Infectious enteritis 1/41 1/128 (0.78 %) 13 Appendicitis 2/41 2/903 (0.22 %) 13, 22 Diverticulitis 1/41 1/775 (0.13 %) 22 Clostridium difficile 1/41 4/775 (0.52 %) 22 Vulvar candiditis 1/41 Not reported (35) Fever 13/41 27/7133 (0.38 %) 1, 8, 10, 13, 15, 21, 24, 25, (26, 27,) 29, 30, 37 Harmful incidents of the surgical site 19/41 65/24,086 (0.27 %) 5, 13, 15, 17, 21, 22, 24, 25, (26, 27,) 29, 30, 32, 33, 35, 37, 39, 40, 41 Surgical site dehiscence 8/41 24/1921 (1.25 %) 13, 15, 17, 22, 25, 29, 32, 33 – vaginal cuff dehiscence 7/41 13/1900 (0.68 %) 13, 15, 17, 22, 25, 29, 32 Seroma 4/41 9/1021 (0.88 %) 5, 21, 22, 37 Fistula 5/41 6/898 (0.67 %) 17, (27,) 29, 30, 32 Port-site hernia 4/41 3/7310 (0.04 %) 22, 24, (29,) 39 Vaginal discharge 3/41 3/228 (1.32 %) 3, 30, (35) Harmful incidents of the urinary system 15/41 33/22,322 (0.15 %) 4, 5, 7, 8, 12, 13, (20,) 24, (27,) 29, 32, (35,) 38, 40, 41 Urologic injury 3/41 3/594 (0.51 %) 8, (20,) 29 – ureteral injury 2/41 1/67 (1.49 %) 8, (20) – bladder injury 1/41 Not reported (20) Ureteral stenosis 1/41 1/31 (3.23 %) 32 Urinary retention 7/41 14/6317 (0.22 %) 4, 5, 12, 24, (27,) 29, 38 Voiding dysfunction 2/41 10/804 (1.24 %) 7, 38 Dysuria 1/41 1/128 (0.78 %) 13 Acute renal failure 3/41 3/20,557 (0.01 %) 24, 40, 41 Harmful incidents of the gastrointestinal system 9/41 32/7424 (0.43 %) 5, 13, (20,) 22, 23, 24, 29, 35, 38 Constipation 4/41 6/6293 (0.10 %) 13, 23, 24, 29 Bowel injury 2/41 1/775 (0.13 %) (20,) 22 Small bowel obstruction 2/41 9/5506 (0.16 %) (22,) 24 Bowel herniation 1/41 1/527 (0.19 %) 29 Constipation haemorrhoids 1/41 1/22 (4.55 %) 5 Harmful incidents of the respiratory system 8/41 29/23,099 (0.13 %) 17, 18, 22, 24, 35, 39, 40, 41 Pneumonia 7/41 12/19,124 (0.06 %) 17, 18, 22, 24, 39, (40,) 41 Unplanned intubation and ventilator treatment 3/41 2/11,696 (0.02 %) 18, (40,) 41 Exacerbation of obstructive pulmonary disease 1/41 5/775 (0.65 %) 22 Harmful incidents of the circulatory system 12/41 93/23,424 (0.40 %) 13, 17, 21, 22, 24, (26,) 28, 30, 35, 39, 40, 41 Thromboembolic disease 11/41 65/23,166 (0.28 %) 13, 17, 21, 22, 24, (26,) 28, 30, 39, 40, 41 – venous thrombo-embolism 4/41 27/12,552 (0.22 %) 21, (26,) 39, 41 – pulmonary embolism 4/41 29/17,743 (0.16 %) 13, 22, 24, 41 Myocardial infarction 4/41 10/18,164 (0.06 %) 24, 28, 39, 41 Cardiac incident 2/41 10/11,592 (0.09 %) 35, 41 Hypertensive urgency 1/41 1/775 (0.13 %) 22 Syncope 1/41 1/775 (0.13 %) 22 Nerve injury 4/41 5/6475 (0.08 %) 17, 22, 24, 38 Lymphedema 3/41 3/914 (0.33 %) 17, 22, 33 Death 3/41 8/11,747 (0.07 %) 17, 28, 41 Pain 22/41 192/9585 (2.00 %) 1, 3, 5, 7, 8, 11, 12, 13, 17, 20, 22, 24, 25, (26, 27,) 29, 30, (31,) 32, 35, 37, 38 Abdominal pain 5/41 47/1031 (4.56 %) 1, 5, 22, 30, 32 Surgical site pain 1/41 Not reported (1) Shoulder pain 1/41 52/138 (37.68 %) 1 Pain due to postoperative ureteral stenosis 1/41 1/21 (4.76 %) 32 Pain due to tethering of the sacral nerve 1/41 1/258 (0.39 %) 35 Chest pain 1/41 5/5506 (0.09 %) 24 Other physiological harmful incidents 15/41 119/7975 (1.49 %) 1, 5, 10, 12, (20,) 22, 24, 25, (26,) 27, 29, 31, 34, 35, 37 Abdominal swelling 1/41 30/138 (21.74 %) 1 Headache 3/41 8/418 (1.91 %) 1, 5, 35 Spinal headache (presumed) 1/41 1/35 (2.86 %) 37 Backache and cramp 1/41 1/22 (4.55 %) 5 Dizziness 4/41 5/1065 (0.47 %) 5, 12, 22, 35 Nausea 7/41 13/5804 (0.22 %) 1, (20, 22,) 24, 27, (29,) 31 Vomiting 5/41 20/5803 (0.34 %) (22,) 24, 25, (29, 37) Decreased oral intake 1/41 Not reported (22) Dehydration 1/41 1/5506 (0.02 %) 24 Fatigue 1/41 31/138 (22.46 %) 1 Soft palate ecchymosis 1/41 1/775 (0.13 %) 22 Pelvic fluid collection 1/41 1/90 (1.11 %) 34 Obstructive ureteral stone 1/41 1/775 (0.13 %) 22 Cutaneous rash after antibiotics 1/41 Not reported (26) Medication misuse 1/41 1/157 (0.64 %) 10 Allergic reaction 1/41 2/775 (0.26 %) 22 Physiological harmful incidents identified by patients 5/41 52/2007 (2.59 %) 7, 19, 20, 29, 30 Suspected infection 1/41 23/728 (3.16 %) 7 Suspected recurrence 1/41 8/728 (1.10 %) 7 Problems related to the Foley catheter 1/41 7/59 (11.86 %) 19 Problems related to the surgical site and wound care 3/41 14/1220 (1.15 %) 20, 29, 30 PSYCHOLOGICAL HARM Anxiety 1/41 6/138 (4.35 %) 1 Notes: The main categories of harmful incidents are highlighted in bold text, under which the subcategories of harmful incidents are listed. Studies in parentheses are not included in the count of total numbers of incidents and participants, either to avoid double reporting from overlapping samples (study IDs 27 and 30) or because the number of incidents were not reported from the study. Table 4 Number of harmful incidents after the various types of surgical treatment. Table 4 dummy alt text HARMFUL INCIDENTS - MAIN CATEGORIES BLEEDING POSTOPERATIVE INFECTIONS OTHER INFECTIONS/ INFLAMMATIONS FEVER SURGICAL SITE PROBLEMS VAGINAL DISCHARGE URINARY SYSTEM GASTROINTESTINAL RESPIRATORY CIRCULATORY SYSTEM NERVE INJURY LYMPHEDEMA DEATH PAIN OTHER PHYSIOLOGICAL HARM PHYSIOLOGICAL HARMFUL INCIDENTS IDENTIFIED BY PATIENTS ANXIETY STUDY ID OF STUDIES THAT INCLUDED THE SURGICAL TREATMENT Hysterectomy 87 1034 55 19 60 3 32 31 28 92 5 3 8 98 40 52 2, 3, 4, 6, 7, 8, 10, 11, 12, 13, 15, 16, 17, 19, 20, 22, 23, 24, 25, 26, 27, 28, 29, 30, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41 Pelvic organ prolapse surgery 32 257 15 4 13 X 17 23 13 18 2 60 14 38 2, 7, 11, 12, 14, 16, 18, 19, 24, 31, 35, 38, 40 Salpingo- oophorectomy 79 63 7 13 29 1 X 4 10 4 3 3 1 106 80 6 1, 3, 9, 10, 15, 17, 22, 23, 26, 27, 33, 34, 37 Lymphadenectomy 19 482 35 3 34 2 1 4 15 64 2 3 7 6 8 2 10, 17, 22, 23, 27, 30, 33, 34, 41 Trachelectomy 7 X 7 6 X 2 2 27, 34 Myomectomy 1 4 5 4 1 9, 21 Ovarian cyst removal 50 1 3 92 71 6 1, 9 Sterilisation X 19 1 1 10 2 1 8 3 5 Note: Presented numbers are the total numbers of harmful incidents reported in studies that included the type of surgery, either as main or concurrent treatment. For studies that included multiple types of surgeries, the number of harmful incidents reported from those studies were added to the counts for all of the included surgical treatments. Studies that did not report number of incidents are also included in the last column. An X in the table indicates that the harmful incident was reported to have occurred in studies listed in the last column but the number of incidents was not reported.
Harmful incidents mapped under dimensions of harm, number of studies reporting the harmful incident, total number of harmful incidents reported and identification numbers (study ID) for studies reporting the harmful incident.
vaginal cuff infection
vaginal cuff dehiscence
ureteral injury
bladder injury
venous thrombo-embolism
pulmonary embolism
Notes: The main categories of harmful incidents are highlighted in bold text, under which the subcategories of harmful incidents are listed. Studies in parentheses are not included in the count of total numbers of incidents and participants, either to avoid double reporting from overlapping samples (study IDs 27 and 30) or because the number of incidents were not reported from the study.
Number of harmful incidents after the various types of surgical treatment.
Note: Presented numbers are the total numbers of harmful incidents reported in studies that included the type of surgery, either as main or concurrent treatment. For studies that included multiple types of surgeries, the number of harmful incidents reported from those studies were added to the counts for all of the included surgical treatments. Studies that did not report number of incidents are also included in the last column. An X in the table indicates that the harmful incident was reported to have occurred in studies listed in the last column but the number of incidents was not reported.
Out of all the main categories of harmful incidents, postoperative infections were reported across the highest number of studies (32/41), followed by bleeding (23/41) and pain (22/41). Urinary tract infection was the subcategory of postoperative infections reported both in the highest number of studies (19/41) and with the highest number of incidents (549/1038 total incidents of postoperative infections), followed by surgical site infection (18/41 studies, 310/1038 total incidents of postoperative infections). The only specified surgical site of infection was the vaginal cuff. The vaginal cuff was also the only specified surgical site where dehiscence was reported. Another identified surgical site problem was fistula. Fistulae were reported from five studies, of which four specified that the fistulae were connected to the urinary tract (study IDs 27, 29, 30, 32). In one of these studies, ureterovaginal fistulae had been the cause of vaginal discharge (study ID 30). Vaginal discharge was identified in three of the included studies. Among the studies that reported of bleeding (23/41), 13 specified vaginal bleeding to have occurred.
Regarding harmful incidents of the urinary system, urinary retention was the subcategory reported in both the highest number of studies (7/41) and with the most incidents (14/33 total incidents of the urinary system). Constipation was the subcategory of harmful incidents related to the gastrointestinal system identified from the highest number of studies (4/41), while small bowel obstruction had the highest number of incidents (9/32 total incidents of the gastrointestinal system). For subcategories of harmful incidents in the respiratory system, pneumonia was reported across the highest number of studies (7/41) and with the most incidents (12/29 total incidents of the respiratory system). Most harmful incidents of the circulatory system were mapped under the subcategory for thromboembolic disease (65/93 total incidents of the circulatory system), which included 29 incidents of pulmonary embolism and 27 incidents of venous thromboembolism. Thromboembolic disease was also the subcategory of harm in the circulatory system that had been reported across the highest number of studies (11/41).
Pain was reported from more than half of the included studies (22/41), out of which only seven specified the site or cause of pain. The highest number of incidents of pain were in the subcategory for shoulder pain (52/192 total incidents of pain), which were all identified from one study. The site of pain specified across the highest number of studies was the abdomen (5/41), which had 47 reported incidents (out of 192 total incidents of pain). The one reported incident of pain due to tethering of a sacral nerve occurred in a study that included pelvic organ prolapse surgery and had resulted in additional surgery for removal of a uterosacral suspension suture. The four incidents of nerve injury were reported from different studies which all included hysterectomy conducted by laparoscopic approach (study IDs 17, 22, 24, 38).
Five studies reported incidents of physiological harm identified by patients that do not fit under any of the other main categories of harmful incidents. Therefore, these harmful incidents are mapped in a separate main category ( Table 3 ). Incidents of ‘suspected recurrence’, as defined in the reporting study, are assumed to refer to the recurrence of pelvic organ prolapse, the condition for which the patients were treated (study ID 7).
The incidents of lymphedema, pelvic fluid collection and death had occurred in studies that included surgical treatment for oncologic indications. One patient had died within two weeks (study ID 17) and another within 30 days after the surgery (study ID 28). For the six remaining incidents, the time from surgery to death had not been noted (study ID 41). None of the studies reported cause of death.
The only psychological harm identified to have occurred following gynaecological ambulatory surgery was anxiety, with all six incidents having been reported from one study (study ID 1). The cause of anxiety was not described in the reporting study.